

S1 Table. Characteristics of secondary malignant neoplasm

Type	No. (%)	Time to SMN (yr), median (range)	Age at SMN (yr), median (range)	SMN-related death, no. (%)
Carcinoma	28 (37.8)	12.7 (5.1-25.3)	20.4 (7.3-36.7)	2 (7.1)
Thyroid cancer	12 (16.2)	9.7 (4.7-19.5)	16.7 (7.3-27.1)	0 (0.0)
Colorectal cancer	7 (9.5)	18.7 (8.0-25.3)	23.8 (15.0-32.4)	1 (14.3)
Renal cell carcinoma	4 (5.4)	9.8 (7.3-22.1)	13.8 (9.4-25.0)	0 (0.0)
Others	5 (6.8)	14.7 (5.1-20.2)	25.1 (15.8-36.7)	1 (20.0)
Sarcoma	24 (32.4)	12.2 (3.2-19.0)	13.8 (4.4-28.3)	7 (29.2)
Osteosarcoma	16 (21.6)	12.3 (3.2-14.5)	12.7 (4.4-25.8)	3 (18.8)
NRSTS	8 (10.8)	11.3 (7.8-19.0)	17.5 (10.1-28.3)	4 (50.0)
Hematologic malignancy	15 (20.3)	3.0 (1.3-18.9)	13.7 (5.5-27.7)	7 (46.7)
AML	6 (8.1)	3.0 (1.3-13.2)	13.9 (5.8-27.7)	3 (50.0)
ALL	2 (2.7)	5.9 (1.7-10.1)	10.0 (6.8-13.3)	0 (0.0)
MDS	6 (8.1)	3.2 (1.6-18.9)	16.4 (5.5-20.9)	4 (66.7)
Others	1 (1.4)	1.3 (1.3-1.3)	11.8 (11.8-11.8)	0 (0.0)
Others	7 (9.5)	13.8 (9.2-20.2)	19.0 (12.1-36.3)	2 (28.6)
Total	74 (100.0)	11.6 (1.3-25.3)	15.5 (4.4-36.7)	18 (24.3)

ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; NRSTS, non-rhabdomyosarcoma soft tissue sarcomas; SMN, secondary malignant neoplasm.